|
🐜
|
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
19 auth.
P. Fenaux,
G. Mufti,
E. Hellstrom-Lindberg,
V. Santini,
C. Finelli,
A. Giagounidis,
R. Schoch,
N. Gattermann,
G. Sanz,
A. List,
...
S. Gore,
J. Seymour,
J. Bennett,
J. Byrd,
J. Backstrom,
L. Zimmerman,
D. McKenzie,
C. Beach,
L. Silverman
|
11 |
2009 |
11
🐜
|
|
🐜
|
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
16 auth.
P. Fenaux,
G. Mufti,
E. Hellström-Lindberg,
V. Santini,
N. Gattermann,
U. Germing,
G. Sanz,
A. List,
S. Gore,
J. Seymour,
...
H. Dombret,
J. Backstrom,
L. Zimmerman,
D. McKenzie,
C. L. Beach,
L. Silverman
|
9 |
2010 |
9
🐜
|
|
🐜
|
Azacitidine (AZA) Treatment Prolongs Overall Survival (OS) in Higher-Risk MDS Patients Compared with Conventional Care Regimens (CCR): Results of the AZA-001 Phase III Study.
17 auth.
P. Fenaux,
G. Mufti,
V. Santini,
C. Finelli,
A. Giagounidis,
R. Schoch,
A. List,
S. Gore,
J. Seymour,
E. Hellström-Lindberg,
...
J. Bennett,
J. Byrd,
J. Backstrom,
L. Zimmerman,
D. McKenzie,
C. Beach,
L. Silverman
|
6 |
2007 |
6
🐜
|
|
🐜
|
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update
14 auth.
P. Fenaux,
G. Mufti,
E. Hellström-Lindberg,
V. Santini,
N. Gattermann,
G. Sanz,
A. List,
S. Gore,
J. Seymour,
J. Backstrom,
...
L. Zimmerman,
D. McKenzie,
C. Beach,
L. Silverman
|
3 |
2008 |
3
🐜
|
|
🐜
|
Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR)
14 auth.
P. Fenaux,
G. Mufti,
E. Hellström-Lindberg,
V. Santini,
N. Gattermann,
G. Sanz,
A. List,
S. Gore,
J. Seymour,
J. Backstrom,
...
L. Zimmerman,
D. McKenzie,
C. Beach,
L. Silverman
|
3 |
2008 |
3
🐜
|
|
🐜
|
Results of a phase 2, multicenter, single‐arm, open‐label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia
15 auth.
M. O’Brien,
Todd A. Alonzo,
T. Cooper,
J. Levine,
P. Brown,
T. Slone,
K. August,
B. Benettaib,
N. Biserna,
Jennifer Poon,
...
M. Patturajan,
N. Chen,
M. Simcock,
L. Zimmerman,
E. Kolb
|
2 |
2021 |
2
🐜
|
|
🐜
|
Comparative trial of aazacitidine versus conventional care in high risk MDS patients: Methodologic challenges in designing an international survival trial.
10 auth.
A. List,
J. Byrd,
P. Fenaux,
S. Gore,
E. Hellström-Lindberg,
G. Mufti,
...
J. Seymour,
L. Silverman,
L. Zimmerman,
C. L. Beach
|
0 |
2003 |
0
🐜
|
